Trial Profile

A Phase 2b Multicenter, Randomized, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icotrokinra (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms FRONTIER 1
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

12 Mar 2024 Results of Improvements in Patient-Reported Symptoms and Signs of Moderate-to-Severe Psoriasis With JNJ-77242113, presented at the American Academy of Dermatology annual Meeting 2024
27 Feb 2024 Results published in the Johnson & Johnson Media Release.
07 Feb 2024 According to a Johnson & Johnson Media Release, data were published in New England Journal of Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com